AR and congestive heart failure: New generation ADTs like abiraterone acetate and enzalutamide directly inhibit androgen synthesis or androgen functions via inhibition of AR, leading to low testosterone levels or lesser action, which increases the risk of developing CVDs like coronary artery disease, congestive heart failure (CHF) and metabolic syndromes like diabetes [31].